Nunavik *Rhodiola rosea* Attenuates Expression of Fear-Potentiated Startle

Anthony Murkar[1,2], **Pamela Kent**[1,2], **Christian Cayer**[1,2,4], **Jon James**[1], **John T. Arnason**[1,4], **Alain Cuerrier**[5], **Zulfiquar Merali**[1,2,3]

[1] University of Ottawa Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada

[2] School of Psychology, University of Ottawa, Ottawa, ON, Canada

[3] Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada

[4] Centre for Advanced Research in Environmental Genomics, Ottawa-Carleton Institute of Biology, University of Ottawa, Ottawa, ON, Canada

[5] Jardin botanique de Montréal, Institut de recherche en biologie végétale, Université de Montréal, Montréal, Canada

Abstract
▼

Rhodiola rosea is a plant with adaptogenic qualities used by Inuit populations of Nunavik, Quebec (Canada) for general mental and physical rejuvenation. Previous studies have demonstrated that the Canadian populations of *R. rosea* significantly attenuate the expression of learned fear and anxiety-like behaviors in rodent models. In order to further characterize the anxiolytic activity of Nunavik *R. rosea,* experiments were conducted to assess the effects of oral administration of the plant extract on both the fear-potentiated startle response and corticosterone levels. Findings suggest that oral administration of *R. rosea* ethanolic extract (75 mg/kg) significantly attenuated fear-potentiated startle, but did not produce any effects on stress-induced secretion of corticosterone.

Rhodiola rosea L. (Crassulaceae) is a flowering perennial native to central Europe and Asia, historically used for the treatment of various mental and physical conditions [1–3]. Research suggests it may have adaptogenic, antidepressant, and/or anxiolytic qualities [4]. The roots of European and Asian specimens may have potential as an intervention for anxiety- and stress-related disorders [5–9].

Recent research has identified isolated populations of *R. rosea* in Nunavik, Quebec (Northern Canada), where it is used for its medicinal properties by local indigenous Inuit populations. Cayer et al. [10] found that phytochemicals present in Nunavik *R. rosea* include those also found in European plant populations (salidroside, tyrosol, rosarin, rosavin, and rosin), and that oral administration of Nunavik *R. rosea* significantly attenuated expression of conditioned fear in animal models.

With this in mind, our research sought to further explore the effects of Nunavik *R. rosea* on the expression and extinction of fear memory using fear-potentiated startle (FPS), an animal model of anxiety-related behaviors (anxiolytic compounds decreases the

FPS response in rodents; see Supporting Information for rodent information and FPS apparatus details; [11]). Additionally, some anxiolytics have significant effects on the release of stress-related glucocorticoid hormones [12,13]. Extracts of European populations of *R. rosea* inhibit stress-induced cortisol secretion [14,15], and plant adaptogens increase stress resistance and reduce the expression of stress-related biomarkers [16–18]. An exploratory analysis was therefore also conducted to assess the effects of *R. rosea* on stress-induced corticosterone secretion.

For fear expression on Day 4, ANOVA results revealed a significant condition by treatment interaction, $F(2,25) = 12.55$, $p < 0.001$ (see Supporting Information for statistical methodology). Follow-up analyses indicated that within the tone + noise condition, animals that received the plant extract had a significantly lower startle amplitude than those who received vehicle alone on the testing day, $p < 0.05$. Animals who received diazepam also exhibited a significantly lower startle potentiation than the controls in the tone + noise condition, $p < 0.05$.

ANOVA results also revealed a significant main effect of the treatment group for percent potentiation (see ◯ **Fig. 1 b**), $F(2,25) = 13.13$, $p < 0.001$. Games-Howell post hoc analyses indicated that the animals who received the plant extract exhibited significantly lower percent potentiation than the controls, $p < 0.01$. Animals who received diazepam also exhibited significantly lower potentiation, $p < 0.05$.

On Day 5, in the absence of *R. rosea* extract administration, there were no significant main effects or interactions in terms of mean startle amplitude (see ◯ **Fig. 2 a**). ANOVA also revealed no significant group difference in terms of percent potentiation (see ◯ **Fig. 2 b**), suggesting the effects of *R. rosea* were acute and had no prolonged effects on fear memory extinction.

In the second experiment, mixed measures ANOVA revealed no significant main effects or interaction effects (see ◯ **Table 1**).

The results support the notion that oral administration of *R. rosea* significantly attenuates the expression of fear-potentiated startle, suggesting it may have anxiolytic properties. Mean startle potentiation was significantly lower on Day 4 for rats who had received the plant extract versus the controls (indeed, the *Rhodiola* effects were slightly more pronounced than those of diazepam). These findings support those presented by Cayer et al. [10], the only other study targeting the anxiolytic properties of Nunavik *R. rosea*.

Although there was a significant reduction in startle potentiation on Day 4, testing in the absence of drug administration revealed some fear reinstatement. On Day 5, there were no significant group differences. Although the plant extract may have anxiolytic properties, its effect is likely limited to mediation of fear expression alone [the plant seemed to have no (or limited) long-term effects on fear memory or extinction]. Nunavik *R. rosea*-related biomarkers are detectable in urine 8 h after administration [19], indicating that active compounds may be excreted via the renal pathway within 8 h of treatment. This, along with our findings, suggests the effects of Nunavik *R. rosea* are likely limited to the period during which they are biologically active, producing no long-term effects on memory following excretion. Diazepam similarly showed no prolonged effects on fear.

Fear memory and expression are thought to be controlled by distinct amygdala microcircuits, with the central nucleus playing a greater role in fear expression [20]. Evidence suggests GABAergic transmission within the basolateral amygdala mediates fear learning [21]. GABAergic signalling also plays a role in the mediation of fear expression within the central nucleus and activity-

Fig. 1 Extract of Nunavik *R. rosea* and diazepam yielded significant suppression of mean startle amplitude (**a**) and percent startle potentiation on Day 4 (**b**).

Fig. 2 Neither *R. rosea* extract nor diazepam yielded significant differences in startle amplitude (**a**) or percent startle potentiation on Day 5 (**b**).

dependent plasticity in the lateral nucleus [20–24]. However, although many anxiolytics (e.g., diazepam) bind to GABA$_A$ receptors, Nunavik *R. rosea* extract and its constituent phytochemicals have low binding affinity for the GABA$_A$ benzodiazepine receptor [10].

While benzodiazepines act as potent anxiolytics, prolonged use causes dependence [25–27], which highlights the need for anxiolytics that act through other mechanisms. Although the Cayer et al. [10] findings do not necessarily exclude the possibility of some GABAergic modulation, it suggests the primary mode of action of *R. rosea* is likely not GABAergic in nature.

Some alternative mechanisms have been suggested to explain the anxiolytic activity of *R. rosea.* For example, *R. rosea* may act as an MOA inhibitor [28]. It has also been shown to interact with both glucocorticoid [29] and neuropeptide Y (NPY) receptors [30]. However, our findings suggested that Nunavik *R. rosea* extract yielded no significant effects on endogenous secretion corticosterone secretion.

Our results are also in contradiction to other findings regarding *R. rosea* extract and glucocorticoid secretion [29]. However, Panossian et al. [29] utilized a 7-day treatment protocol, which might account for the difference in glucocorticoid effects.

Research suggests the primary mechanism of Nunavik *R. rosea* is neither glucocorticoid-based nor GABAergic (see Cayer et al. [10]). Although the results of the present investigation are positive, they are limited in that they do not address this mechanism directly. Future research should therefore explore the mechanism responsible for the anxiolytic effects of Nunavik *R. rosea,* possibly targeting the role of NPY receptors or monoamine oxidase [28, 30].

Table 1 Mean corticosterone (ng/sample) by treatment group.

	Treatment group	Mean corticosterone (ng/sample)	Standard deviation
30 Minutes	Vehicle	3864.48	2203.49
	Diazepam	3047.89	2851.58
	R. rosea	4040.05	1855.77
60 Minutes	Vehicle	1528.87	702.13
	Diazepam	1241.07	1528.35
	R. rosea	2224.99	1671.78
5 Days (Baseline)	Vehicle	1232.22	1486.07
	Diazepam	932.08	774.05
	R. rosea	1147.85	958.37

Materials and Methods
▼

R. rosea roots were collected near Kuujjuaq, Nunavik, Quebec (Canada). Samples were identified by Alain Cuerrier (University of Montreal, Canada). A voucher specimen was deposited in the University of Ottawa Herbarium, UOH#19 847. HPLC data (chromatogram of the plant extract) is available in Cayer et al. [10], and the same batch of *R. rosea* extract was used for both Cayer et al. [10] and this paper. Roots were dried in a commercial plant dryer at 35 °C and ground with a Wiley Mill (2 mm mesh size). Roots were extracted with 90 % ethanol (10 m/v) and vacuum filtered through Whatmann no. 1 filter paper. The residue was re-extracted with 90 % ethanol (5 m/v) twice and filtered. The filtrates

were combined, the solvent was roto-evaporated at 40 °C, and the extract lyophilized (percent yield = 7 %). The extract was stored at 4 °C and protected from light.

All experiments were conducted in accordance with the guidelines established by the Canadian Council on Animal Care and approved by the University of Ottawa Animal Care Committee (protocol approved September 26 2014, ACC-2011-006).

Rats were randomly assigned to treatment groups: *R. rosea* (75 mg/kg dose), vehicle, or diazepam (1 mg/kg dose, positive control; produced by Sandoz, original concentration 5 mg/mL in 40 % propylene glycol, 10 % alcohol, and 50 % water). *R. rosea* ethanolic extract and diazepam were suspended in 50 % sweetened condensed milk (vehicle). Controls received the vehicle alone.

Animals in the *R. rosea* group were treated over 3 days, following the procedures outlined by Cayer et al. [10], with the final dose administered 50 min prior to testing. Animals in the other groups received the vehicle alone on those days. The positive control group received an acute dose of diazepam administered 50 min prior to testing on the final day. All treatments were administered in a volume of 2 mL/kg body weight.

On Day 1, animals were placed inside the startle chamber and exposed to random bursts of white noise (95, 110, and 115 dB) for acclimatization and to obtain baseline startle amplitudes. On Day 2, animals were exposed to a conditioning paradigm where a tone was paired with subsequent foot shock (1.0 mA, 0.5 s duration) during the last 500 ms of the tone. The Day 2 conditioning consisted of seven CS-US pairings over the course of nine minutes, (average 60 s between pairings, interval lengths randomized).

Forty-eight hours later (Day 4), animals were re-exposed to the conditioning chamber. Over the course of 25 min, 20 trials of 110 dB white noise bursts (at randomized time intervals averaging 60 s) were presented, followed by 5 trials where the tone was presented along with 110 dB white noise bursts.

Forty-eight hours later (Day 5), animals were re-exposed to the conditioning chamber in the absence of any drug administration to measure long-term/extinction effects. Over 25 min, 20 trials of 110 dB white noise bursts (at randomized time intervals averaging 60 seconds) were presented, followed by 5 trials where the tone was presented with 110 dB white noise bursts.

The percentage of fear-potentiated startle was computed as [(startle amplitude on tone–noise minus noise-alone trials)/noise-alone trials] × 100

Supporting information

Details on the apparatus, statistical analyses, and animals are available as Supporting Information.

Conflict of Interest

▼

The authors have read and understood Planta Medica Letters policy on the declaration of interests and declare that we have no competing interests.

References

1 *Alm T.* Ethnobotany of *Rhodiola rosea* (Crassulaceae) in Norway. SIDA Contrib Bot 2004; 21: 321–344

2 *Khanum F, Bawa A, Singh B.* Rhodiola rosea: A versatile adaptogen. Compr Rev Food Sci Food Sav 2005; 4: 55–62

3 *Panossian A, Wikman G, Sarris J.* Rosenroot (*Rhodiola rosea*): traditional use, chemical composition, pharmacology, and clinical efficacy. Phytomedicine 2010; 17: 481–493

4 *Panossian A, Wagner H.* Stimulating effect of adaptogens: an overview with particular reference to their efficacy following single dose administration. Phytother Res 2005; 19: 819–838

5 *Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A.* Clinical trial of *Rhodiola rosea* L. extract SHR-5 in the treatment of mild to moderate depression. Nor J Psychiatry 2007; 61: 2343–2348

6 *Hung S, Perry R, Ernst E.* The effectiveness and efficacy of *Rhodiola rosea* L.: a systematic review of randomized clinical trials. Phytomedicine 2011; 18: 235–244

7 *Mattioli L, Perfumi M. Rhodiola rosea* L. extract reduces stress and CRF-induced anorexia in rats. J Psychopharmacol 2007; 21: 742–750

8 *Punja S, Shamseer L, Olson K, Vohra S. Rhodiola rosea* for mental and physical fatigue in nursing students: a randomized controlled trial. PLoS One 2014; 9: e108416

9 *Spasov AA, Wikman GK, Mandrikov VB, Mironova IA, Neumoin VV.* A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of *Rhodiola rosea* SHR-5 on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen. Phytomedicine 2000; 7: 85–89

10 *Cayer C, Ahmed F, Filion V, Saleem A, Cuerrier A, Allard M, Rochefort G, Merali Z, Arnason JT.* Characterization of the anxiolytic activity of Nunavik *Rhodiola rosea*. Planta Med 2013; 79: 1385–1391

11 *Davis M, Falls W, Campeau S, Kim M.* Fear-potentiated startle: a neural and pharmacological analysis. Behav Brain Res 1993; 58: 175–198

12 *Matheson GK, Gage D, White G, Dixon V, Gipson D.* A comparison of the effects of buspirone and diazepam on plasma corticosterone levels in rat. Neuropharmacology 1988; 27: 823–830

13 *Peričić D, Lakić N, Manew H.* Effect of diazepam on corticosterone levels. Psychopharmacology 1984; 83: 79–81

14 *Olsson EM, von Schéele B, Panossian AG.* A randomized double-blind placebo controlled parallel group study of SHR-5 extract of *Rhodiola rosea* roots as treatment for patients with stress related fatigue. Planta Med 2009; 74: 105–112

15 *Panossian A, Wikman G.* Evidence-based efficacy of adaptogens in fatigue, and molecular mechanisms related to their stress-protective activity. Curr Clin Pharmacol 2009; 4: 198–219

16 *Darbinyan V, Kteyan A, Panossian A, Gabrielian E, Wikman G, Wagner H. Rhodiola rosea* in stress induced fatigue – a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. Phytomedicine 2000; 7: 365–371

17 *Lishmanov Y, Krylatov A, Maslov L, Naryzhnaya N, Zamotrinskii A.* The effect of extract from *Rhodiola rosea* on the level of inducible HSP-70 in the myocardium during stress. Bull Exp Bio Med 1996; 121: 235–237

18 *Wiegant F, Surinova S, Ytsma E, Langelaar-Makkinje M, Wikman G, Post JA.* Plant adaptogens increase lifespan and stress resistance in *C. elegans*. Biogerentology 2009; 10: 27–42

19 *Ahmed F. Rhodiola rosea* L. – An Evaluation of Safety and Efficacy in the Context of a neurological Disorder, Alzheimer Disease [Dissertation]. Ottawa: University of Ottawa; 2015

20 *Duvarci S, Pare D.* Amygdala microcircuits controlling learned fear. Neuron 2014; 82: 966–980

21 *Pare D, Royer S, Smith Y, Lang E.* Contextual inhibitory gating of impulse traffic in the intra-amygdaloid network. Ann N Y Acad Sci 2003; 985: 247–254

22 *Chhatwal J, Myers K, Ressler K, Davis M.* Regulation of gephyrin and GABAa receptor binding within the amygdala after fear acquisition and extinction. J Neurosci 2005; 25: 502–506

23 *Shaban H, Humeau Y, Herry C, Cassasus G, Shigemoto R, Ciocchi S, Barbieri S, van der Putten H, Kaupmann K, Bettler B, Lüthi A.* Generalization of amygdala LTP and conditioned fear in the absence of presynaptic inhibition. Nat Neurosci 2006; 9: 1028–1035

24 *Watanabe Y, Ikegaya Y, Saito H, Abe K.* Roles of GABAa, NDMA and muscarinic receptors in the induction of long-term potentiation in the medial and lateral amygdala *in vitro*. Neurosci Res 1995; 21: 317–322

25 *Miller NS, Gold MS.* Benzodiazepines: a major problem. Introduction. J Subst Abuse Treat 1991; 8: 3–7

26 *Rooney S, Kelly G, Bamford L, Sloan D, O'Connor JJ.* Co-abuse of opiates and benzodiazepines. Ir J Med Sci 199; 168: 36–41

27 *Wafford K.* GABAa receptor subtypes: any clues to the mechanism of benzodiazepine dependence? Curr Opin Pharmacol 2005; 5: 47–52

28 *Van Dierman D, Marston A, Bravo J, Reist M, Carrupt PA, Hostettman K.* Monoamine oxidase inhibition by *Rhodiola rosea* L. roots. J Ethnopharmacol 2009; 122: 397–401

29 *Panossian A, Hambartsumyan M, Hovanissian A, Wikman G.* The adaptogens *rhodiola* and *schizandra* modify the response to immobilization stress in rabbits by suppressing the increase of phosphorylated stress-activated protein kinase, nitric oxide, and cortisol. Drug Target Insights 2007; 2: 39–54

30 *Larhammar D, Salaneck E.* Molecular evolution of NPY receptor subtypes. Neuropeptides 2004; 38: 141–151

Correspondence
Zul Merali
1145 Carling Ave
Ottawa, ON K1Z 7K4
Canada
Phone: + 1 61 37 22 65 21
Fax: + 1 61 37 92 39 35
zul.merali@theroyal.ca